adverse effects
FDA issues gliptin joint pain warning
September 1, 2015Manufacturing and Production DPP-4 inhibitors, ESC, FDA, TECOS, adverse effects, drug safety, gliptins, safety alert, safety warning
The FDA has issued a safety alert, warning of joint pain caused by the gliptins, a common class of drugs …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
